Just caught that Stryker went through their CFO transition last month - Glenn Boehnlein finally called it after 22 years in the role. Pretty wild to see someone stick around that long in a finance position at a major corporation. Preston Wells took over starting April 1st, and honestly the whole thing reads like a textbook internal succession play. Wells was already running the Orthopaedics Group finances, so it's not like they're bringing in some random outsider. Kevin Lobo even made a point about how Glenn Boehnlein invested in developing talent, which is probably why Wells was ready for the jump. What's interesting is Wells brings his own solid background - 17 years doing finance stuff at Dialight and Johnson & Johnson before Stryker, so he's not exactly green. The insider trading data shows Glenn Boehnlein sold off some shares before stepping back, which you'd kind of expect. Bigger picture, the medical tech space seems to be handling these leadership transitions pretty smoothly these days. Stryker's positioning this as continuity rather than disruption, which makes sense when you're promoting from within. Wonder how the market's gonna feel about the change longer term.